Overview
The company is focused on the delivery of IT- enabled (majoring in SAP) business change consultancy services, taking an innovative, technology-driven approach to projects and utilising industry-leading tools to drive sustainable changes at all levels of its clients’ organisations.
Operating on an international basis, the company has experienced rapid expansion since its foundation, with its innovative approach enabling it to provide unique and highly effective solutions, facilitating the development of an excellent reputation within its sector.
Having built up a strong and respected business, our clients are now offering the company for sale as part of their retirement plans.
Key Highlights
• Benefitting from a wealth of expertise across a broad range of markets, the company is uniquely placed to provide creative solutions to complex problems, supporting the development of direct relationships with major clients.
• The company predominantly operates in the pharmaceutical, aerospace, defence and IT sectors, and primarily works with organisations based within the EMEA.
• Maintains long-standing relationships with significant, blue-chip clients, several of which have remained in place for over nine years.
• Utilises a highly experienced team of directly employed consultants and a network of over 200 skilled associates to provide support for a multitude of projects, with the current management team possessing the skills and expertise required to independently manage and grow the business on an ongoing basis.
• All employees operate remotely, with scope for the business to be efficiently managed from any location across the globe.
Financial Highlights
• Achieved YE23 management turnover in excess of £5.5 million, with an adjusted EBITDA of circa £1 million.
• Maintains consistently strong gross profit and adjusted EBITDA margins, averaging 29% and 19%, respectively, across the last five years.
• Strong pipeline in place, including commitments for the coming year valued at £4 million, with additional business development (new and existing clients) at circa £8 million.
• The company has been awarded approved supplier status with a number of major clients, having also secured a three-year global master service agreement (MSA) with an eleven-billion-dollar turnover company in the pharmaceutical sector, ensuring that future revenue is secure.
